Welcome to our dedicated page for Progyny news (Ticker: PGNY), a resource for investors and traders seeking the latest updates and insights on Progyny stock.
Progyny, Inc. (PGNY) generates a steady flow of news as a global leader in women’s health and family building solutions listed on the Nasdaq Global Select Market. Company updates frequently focus on fertility and women’s health benefits, research on employee and member needs, and financial performance, giving investors and benefits professionals insight into how Progyny’s model is evolving.
News coverage commonly includes quarterly earnings results and financial guidance, which are also referenced in the company’s Form 8-K filings. These releases discuss revenue from fertility benefit services and pharmacy benefit services, member engagement trends, client additions, and key metrics such as assisted reproductive treatment cycles and utilization rates. Investors following PGNY news can see how changes in client count, covered lives, and engagement influence the company’s reported results and outlook.
Progyny also issues news about new programs and product expansions. For example, it has announced pregnancy, postpartum, and menopause programs for global employers that complement its existing global fertility and family building offering, along with details on features such as Global Care Advocates, knowledge centers, and country-specific navigator support. These announcements provide context on how Progyny is extending its reach across the women’s health continuum and into global markets.
Another important category of news involves research and thought leadership. Progyny has released studies on men’s fertility experiences and on gaps between employee expectations and employer offerings in women’s health benefits, conducted with Dynata. These stories highlight barriers such as stigma, cost, and benefit complexity, and they underscore the company’s focus on data-driven insights for employers.
Additional news items may cover conference participation, leadership recognition, and partnerships, such as appearances at healthcare conferences and recognition of the CEO as a Champion for Women’s Health by the World Economic Forum and the Global Alliance for Women’s Health. For anyone tracking PGNY, this news page offers a centralized view of operational, financial, and strategic developments over time.
Welltok has integrated Maven and Progyny into its Connect Partner Ecosystem, enhancing employer offerings for family planning and fertility benefits. The inclusion aims to attract and retain talent by providing comprehensive fertility programs. Maven delivers personalized maternity support, resulting in a 90% return-to-work rate and 32% fewer NICU admissions. Progyny boasts a 25% higher live birth rate than national averages and significantly reduces healthcare costs. This partnership underscores Welltok's commitment to improving maternal health and supporting diverse family-building needs.
Progyny, a leader in fertility benefits management, announced that CEO David Schlanger and CFO Mark Livingston will engage in a fireside chat at the BofA Securities 2021 Health Care Conference on May 12, 2021, at 10:15 A.M. ET. The discussion aims to highlight Progyny's innovative fertility solutions and their impact on employers and patients. A live audiocast and replay will be available on Progyny’s investor website. The company, headquartered in New York City, has received accolades for its growth and leadership in redefining family building benefits.
Progyny, Inc. (PGNY) reported a record revenue of $122.1 million for Q1 2021, marking a 51% increase from the previous year. This growth is attributed to a higher client base and demand for fertility benefits. The company has issued a revenue guidance of $126.0 million to $131.0 million for Q2 2021, reflecting a growth of 95% to 103%. Net income surged to $15.2 million, up 318% year-over-year. Progyny's solid financial performance is complemented by increased operating efficiencies and positive industry trends.
Progyny, Inc. (Nasdaq: PGNY) will report its financial results for Q1 2021 on May 6, 2021, after market close. The company specializes in fertility and family building benefits. A conference call will follow at 4:45 PM ET, with access details for both U.S. and international participants provided. An audio replay will be available until May 14, 2021. Progyny is recognized for its innovative approach in the fertility sector, supporting patients and employers alike. Further information can be found on their website.
Progyny, Inc. (Nasdaq: PGNY) reported a record revenue of $100.3 million for Q4 2020, a 54% increase from Q4 2019. For FY 2020, total revenue reached $344.9 million, up 50% year-over-year. The company also projected 2021 revenue between $520 million and $540 million, reflecting growth of 51% to 57%. Key highlights included a tripled Adjusted EBITDA and significant growth in both fertility and pharmacy benefit services. Despite challenges from the COVID-19 pandemic, Progyny's performance showcased its market resilience and expansion capabilities.
Progyny, a leader in fertility benefits management, announced its participation in the 10th Annual SVB Leerink Global Healthcare Conference on February 26, 2021, at 8:40 A.M. ET. Chief Executive Officer David Schlanger and Chief Financial Officer Mark Livingston will engage in a fireside chat at the event. Interested parties can access the live audiocast and replay via Progyny’s website. The company is recognized for redefining fertility and family building solutions, benefiting employers and patients alike.
Progyny, Inc. (Nasdaq: PGNY), a leader in fertility benefits management, will release its financial results for Q4 and full year 2020 on February 24, 2021, post-market. A conference call will follow at 4:45 PM ET, offering insights into the company's performance. Participants can join via specified dial-in numbers and passcodes, with a replay available until March 3, 2021. The firm emphasizes its innovative approach to fertility solutions, aiming to benefit employers, patients, and healthcare providers. Progyny has received accolades from various organizations, highlighting its industry leadership.
Progyny, a leading fertility benefits management company, announced that CEO David Schlanger will present at the 39th Annual JP Morgan Healthcare Conference on January 12, 2021, at 3:40 P.M. Eastern Time. Following the presentation, President and COO Pete Anevski and CFO Mark Livingston will join Schlanger for a breakout session. A live audiocast and replay will be available on Progyny's website. The company is dedicated to redefining fertility benefits, providing comprehensive solutions that benefit employers, patients, and healthcare providers.
Progyny (Nasdaq: PGNY) has announced the addition of two new board members: Malissia R. Clinton and Roger Holstein, effective November 16, 2020. Clinton, with over 25 years in various industries, will serve on the Nominating and Governance Committee, while Holstein, a healthcare industry veteran, will join the Compensation Committee. Their expertise in healthcare and technology aims to provide strategic guidance as Progyny transitions to a high-growth leader in fertility benefits management. The board now consists of nine directors, enhancing the company's governance and industry insights.
Progyny, Inc. (Nasdaq: PGNY), a leader in fertility benefits management, announced that CEO David Schlanger will participate in a fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference. The pre-recorded chat will be accessible from November 23 on Progyny’s website. Additionally, the company will conduct one-on-one meetings on December 1, with requests made exclusively through Piper Sandler. Progyny's innovative benefits solution aims to redefine fertility support, offering education, access to specialists, and improved clinical outcomes while reducing costs for employers.